Sun Pharma subsidiaries settle US antitrust pricing lawsuit

Regulatory & Legal View source PDF Explain this filing

SUNPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.3%Reaction day

₹1840.00

prior close

₹1854.60

announcement price

After-mkt

timing

Nifty 100market-1.4%+1.2% vs market

Pharmaceuticals peers, median of 172sector-1.9%+1.6% vs sector

On the reaction day the stock moved 1.2 pts more than Nifty 100 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.9

10m

-0.7

15m

-0.7

30m

-1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.3-1.4+1.2-1.9+1.6

Next day

+0.7-1.1+1.8-2.1+2.8

+1.1-0.7+1.8-1.2+2.3

+0.7-0.2+0.8-0.4+1.1

+1.9+0.1+1.8+0.2+1.7

+0.5-0.3+0.9-0.1+0.6

+0.5-1.3+1.9-0.2+0.8

15d

-3.3-3.5+0.2-3.0-0.3

-4.1-2.3-1.8-6.0+1.9

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sun Pharma's US subsidiaries SPII, Taro Ltd, and Taro USA have signed a settlement agreement with a plaintiff in the In re Generic Pharmaceuticals Pricing Antitrust Litigation in the US District Court for the Eastern District of Pennsylvania. The settlement amount is confidential. Under the agreement, the subsidiaries get a full release of all claims in this case. The settlement is entered without any admission of wrongdoing. Other terms remain confidential.

Likely market impact

Removes one US antitrust lawsuit overhang. Confidential amount and no admission of wrongdoing limit financial and reputational impact.